As Johnson & Johnson (JNJ) Share Value Rose, Shareholder Calamos Advisors LLC Has Lifted Its Holding

February 25, 2018 - By Winifred Garcia

Investors sentiment is 0.83 in Q3 2017. Its the same as in 2017Q2. It has no change, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Douglass Winthrop Advsrs Llc owns 1.49% invested in Johnson & Johnson (NYSE:JNJ) for 197,776 shares. New Jersey Better Educational Savings holds 2.19% or 20,000 shares. Pettee Invsts Inc reported 12.18% in Johnson & Johnson (NYSE:JNJ). Ssi Inv Inc holds 8,655 shares or 0.1% of its portfolio. Acadian Asset Lc invested in 1.05M shares or 0.6% of the stock. Alpine Global Mgmt Limited Company holds 0.12% or 3,124 shares in its portfolio. Outfitter Advsr Ltd reported 1.12% stake. Becker Mngmt has invested 1.94% of its portfolio in Johnson & Johnson (NYSE:JNJ). Yorktown Mngmt & Research invested in 0.35% or 10,400 shares. Columbia Asset Mngmt invested in 66,872 shares. Norinchukin Natl Bank The stated it has 0.96% in Johnson & Johnson (NYSE:JNJ). State Treasurer State Of Michigan invested in 1.01 million shares or 1.06% of the stock. Caz Investments LP invested in 7,580 shares or 1.21% of the stock. Thompson Siegel And Walmsley Ltd Liability Corporation invested in 0.15% or 94,001 shares. Roof Eidam Maycock Adv reported 17,145 shares.

Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity.

Calamos Advisors Llc increased its stake in Johnson & Johnson (JNJ) by 22.52% based on its latest 2017Q3 regulatory filing with the SEC. Calamos Advisors Llc bought 266,023 shares as the company’s stock rose 6.85% with the market. The institutional investor held 1.45 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $188.13 million, up from 1.18 million at the end of the previous reported quarter. Calamos Advisors Llc who had been investing in Johnson & Johnson for a number of months, seems to be bullish on the $354.67B market cap company. The stock increased 1.62% or $2.11 during the last trading session, reaching $132.02. About 5.13M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since February 25, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

Calamos Advisors Llc, which manages about $26.54 billion and $12.93 billion US Long portfolio, decreased its stake in Ctrip.Com Intl Ltd (Prn) by 25.61M shares to 28.12 million shares, valued at $31.97M in 2017Q3, according to the filing. It also reduced its holding in Merck & Co (NYSE:MRK) by 107,402 shares in the quarter, leaving it with 1.15 million shares, and cut its stake in Crown Castle Intl Corp (NYSE:CCI).

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: “Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next …” on February 20, 2018, also with their article: “Johnson & Johnson beefs up its surgery robotics tech with acquisition of …” published on February 21, 2018, published: “Why I Recently Bought Johnson & Johnson” on February 15, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: and their article: “Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 26, 2018” published on February 23, 2018 as well as‘s news article titled: “Can Johnson & Johnson Replace Remicade for $100 Million Upfront?” with publication date: February 21, 2018.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson has $170.0 highest and $90 lowest target. $137.72’s average target is 4.32% above currents $132.02 stock price. Johnson & Johnson had 89 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, September 13 with “Hold”. The firm has “Buy” rating given on Friday, June 2 by BMO Capital Markets. JP Morgan downgraded Johnson & Johnson (NYSE:JNJ) on Tuesday, January 2 to “Neutral” rating. Leerink Swann maintained it with “Buy” rating and $165.0 target in Wednesday, October 18 report. The rating was maintained by Barclays Capital with “Equal-Weight” on Wednesday, October 18. The firm earned “Buy” rating on Wednesday, October 19 by UBS. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Thursday, October 5 by BMO Capital Markets. The firm has “Sell” rating given on Friday, July 21 by Atlantic Securities. Vetr downgraded the stock to “Strong-Buy” rating in Monday, August 31 report. The stock has “Equal-Weight” rating by Barclays Capital on Tuesday, November 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.